IL-6 roles – Molecular pathway and clinical implication in pancreatic cancer – A systemic review

Immunology Letters

Volumn 181, Issue , 2017, Pages 45-50

  Pop, Vlad Vasile ^a   Seicean, Andrada ^a,b   Lupan, Iulia ^c   Samasca, Gabriel ^a,d   Burz, Claudia Cristina ^a,e  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Octavian Fodor Regional Institute of Gastroenterology and Hepatology   (Romania)

^c BABE BOLYAI UNIVERSITY   (Romania)

^d Emergency Hospital for Children   (Romania)

^e THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

Author keywords

Interleukin 6; Oncogenesis; Pancreatic cancer; Prognosis

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE 2; STAT3 PROTEIN; TRANSCRIPTION FACTOR; TUMOR MARKER;

CACHEXIA; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CYTOKINE PRODUCTION; DEPRESSION; DISEASE ASSOCIATION; HUMAN; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TUMOR MICROENVIRONMENT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS;

BIOMARKERS, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; PANCREATIC NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR MICROENVIRONMENT;

EID: 84997294263     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2016.11.010     Document Type: Review

References (65)

1. [1] Humphris, J.L., Johns, A.L., Simpson, S.H., Cowley, M.J., Pajic, M., Chang, D.K., Nagrial, A.M., Chin, V.T., Chantrill, L.A., Pinese, M., Mead, R.S., Gill, A.J., Samra, J.S., Kench, J.G., Musgrove, E.A., Tucker, K.M., Spigelman, A.D., Waddell, N., Grimmond, S.M., Biankin, A.V. I, Australian pancreatic cancer genome, clinical and pathologic features of familial pancreatic cancer. Cancer 120:23 (2014), 3669–3675.
2. [2] Chen, J., Wang, S., Su, J., Chu, G., You, H., Chen, Z., Sun, H., Chen, B., Zhou, M., Interleukin-32alpha inactivates JAK2/STAT3 signaling and reverses interleukin-6-induced epithelial-mesenchymal transition, invasion, and metastasis in pancreatic cancer cells. OncoTargets Ther. 9 (2016), 4225–4237.
3. [3] Ducreux, M., Cuhna, A.S., Caramella, C., Hollebecque, A., Burtin, P., Goere, D., Seufferlein, T., Haustermans, K., Van Laethem, J.L., Conroy, T., Arnold, D., E.G. Committee, Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 26:Suppl. 5 (2015), v56–v68.
4. [4] Holmer, R., Goumas, F.A., Waetzig, G.H., Rose-John, S., Kalthoff, H., Interleukin-6: a villain in the drama of pancreatic cancer development and progression. Hepat. Pancreat. Dis. Int.: HBPD INT 13:4 (2014), 371–380.
5. [5] Block, K.M., Hanke, N.T., Maine, E.A., Baker, A.F., IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell lines. Pancreas 41:5 (2012), 773–781.
6. [6] Heinrich, P.C., Behrmann, I., Muller-Newen, G., Schaper, F., Graeve, L., Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334:Pt. 2 (1998), 297–314.
7. [7] Arshad, A., Chung, W.Y., Steward, W., Metcalfe, M.S., Dennison, A.R., Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil. HPB (Oxford) 15:6 (2013), 428–432.
8. [8] Li, R., Hou, J., Xu, Q., Liu, Q.J., Shen, Y.J., Rodin, G., Li, M., High level interleukin-6 in the medium of human pancreatic cancer cell culture suppresses production of neurotransmitters by PC12 cell line. Metab. Brain Dis. 27:1 (2012), 91–100.
9. [9] Talar-Wojnarowska, R., Gasiorowska, A., Smolarz, B., Romanowicz-Makowska, H., Kulig, A., Malecka-Panas, E., Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig. Dis. Sci. 54:3 (2009), 683–689.
10. [10] Munoz-Canoves, P., Scheele, C., Pedersen, B.K., Serrano, A.L., Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword?. FEBS J. 280:17 (2013), 4131–4148.
11. [11] Lesina, M., Wormann, S.M., Neuhofer, P., Song, L., Algul, H., Interleukin-6 in inflammatory and malignant diseases of the pancreas. Semin. Immunol. 26:1 (2014), 80–87.
12. [12] Okitsu, K., Kanda, T., Imazeki, F., Yonemitsu, Y., Ray, R.B., Chang, C., Yokosuka, O., Involvement of interleukin-6 and androgen receptor signaling in pancreatic cancer. Genes Cancer 1:8 (2010), 859–867.
13. [13] Feurino, L.W., Zhang, Y., Bharadwaj, U., Zhang, R., Li, F., Fisher, W.E., Brunicardi, F.C., Chen, C., Yao, Q., Min, L., IL-6 stimulates Th2 type cytokine secretion and upregulates VEGF and NRP-1 expression in pancreatic cancer cells. Cancer Biol. Ther. 6:7 (2007), 1096–1100.
14. [14] Heinrich, P.C., Behrmann, I., Haan, S., Hermanns, H.M., Muller-Newen, G., Schaper, F., Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J 374:Pt. 1 (2003), 1–20.
15. [15] Chan, C., Lin, H.J., Lin, J., Stress-associated hormone, norepinephrine, increases proliferation and IL-6 levels of human pancreatic duct epithelial cells and can be inhibited by the dietary agent, sulforaphane. Int. J. Oncol. 33:2 (2008), 415–419.
16. [16] Nagasaki, T., Hara, M., Shiga, K., Takeyama, H., Relationship between inflammation and cancer progression: recent advances in interleukin-6 signaling and its blockage in cancer therapy. Recept. Clin. Investig., 1(3), 2014.
17. [17] Lesina, M., Kurkowski, M.U., Ludes, K., Rose-John, S., Treiber, M., Kloppel, G., Yoshimura, A., Reindl, W., Sipos, B., Akira, S., Schmid, R.M., Algul, H., Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19:4 (2011), 456–469.
18. [18] Shuai, K., Regulation of cytokine signaling pathways by PIAS proteins. Cell Res. 16:2 (2006), 196–202.
19. [19] O'Shea, J.J., Gadina, M., Schreiber, R.D., Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109:Suppl (2002), S121–S131.
20. [20] Miron, N., Miron, M.M., Milea, V.G., Cristea, V., Proinflammatory cytokines: an insight into pancreatic oncogenesis. Roum. Arch. Microbiol. Immunol. 69:4 (2010), 183–189.
21. [21] Wigmore, S.J., Fearon, K.C., Sangster, K., Maingay, J.P., Garden, O.J., Ross, J.A., Cytokine regulation of constitutive production of interleukin-8 and −6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int. J. Oncol. 21:4 (2002), 881–886.
22. [22] Huang, C., Yang, G., Jiang, T., Zhu, G., Li, H., Qiu, Z., The effects and mechanisms of blockage of STAT3 signaling pathway on IL-6 inducing EMT in human pancreatic cancer cells in vitro. Neoplasma 58:5 (2011), 396–405.
23. [23] Bharadwaj, U., Marin-Muller, C., Li, M., Chen, C., Yao, Q., Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis 32:7 (2011), 1013–1024.
24. [24] Bharadwaj, U., Marin-Muller, C., Li, M., Chen, C., Yao, Q., Mesothelin confers pancreatic cancer cell resistance to TNF-alpha-induced apoptosis through Akt/PI3K/NF-kappaB activation and IL-6/Mcl-1 overexpression. Mol. Cancer, 10, 2011, 106.
25. [25] Huang, L., Hu, B., Ni, J., Wu, J., Jiang, W., Chen, C., Yang, L., Zeng, Y., Wan, R., Hu, G., Wang, X., Transcriptional repression of SOCS3 mediated by IL-6/STAT3 signaling via DNMT1 promotes pancreatic cancer growth and metastasis. J. Exp. Clin. Cancer Res.: CR, 35, 2016, 27.
26. [26] Xu, J., Xiong, G., Cao, Z., Huang, H., Wang, T., You, L., Zhou, L., Zheng, L., Hu, Y., Zhang, T., Zhao, Y., PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value. J. Exp. Clin. Cancer Res.: CR, 35(1), 2016, 133.
27. [27] Fofaria, N.M., Srivastava, S.K., STAT3 induces anoikis resistance, promotes cell invasion and metastatic potential in pancreatic cancer cells. Carcinogenesis 36:1 (2015), 142–150.
28. [28] Weidner, N., Semple, J.P., Welch, W.R., Folkman, J., Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N. Engl. J. Med. 324:1 (1991), 1–8.
29. [29] Miyamoto, Y., Hosotani, R., Doi, R., Wada, M., Ida, J., Tsuji, S., Kawaguchi, M., Nakajima, S., Kobayashi, H., Masui, T., Imamura, M., Interleukin-6 inhibits radiation induced apoptosis in pancreatic cancer cells. Anticancer Res. 21:4A (2001), 2449–2456.
30. [30] Liu, X., Wang, J., Wang, H., Yin, G., Liu, Y., Lei, X., Xiang, M., REG3A accelerates pancreatic cancer cell growth under IL-6-associated inflammatory condition: involvement of a REG3A-JAK2/STAT3 positive feedback loop. Cancer Lett. 362:1 (2015), 45–60.
31. [31] Zhang, Y., Bharadwaj, U., Logsdon, C.D., Chen, C., Yao, Q., Li, M., ZIP4 regulates pancreatic cancer cell growth by activating IL-6/STAT3 pathway through zinc finger transcription factor CREB. Clin. Cancer Res. 16:5 (2010), 1423–1430.
32. [32] Kang, R., Tang, D., Lotze, M.T., Zeh, H.J. 3rd, AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway. Autophagy 8:6 (2012), 989–991.
33. [33] Dandrea, M., Donadelli, M., Costanzo, C., Scarpa, A., Palmieri, M., MeCP2/H3meK9 are involved in IL-6 gene silencing in pancreatic adenocarcinoma cell lines. Nucleic Acids Res. 37:20 (2009), 6681–6690.
34. [34] Mace, T.A., Bloomston, M., Lesinski, G.B., Pancreatic cancer-associated stellate cells: a viable target for reducing immunosuppression in the tumor microenvironment. Oncoimmunology, 2(7), 2013, e24891.
35. [35] Mace, T.A., Ameen, Z., Collins, A., Wojcik, S., Mair, M., Young, G.S., Fuchs, J.R., Eubank, T.D., Frankel, W.L., Bekaii-Saab, T., Bloomston, M., Lesinski, G.B., Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res. 73:10 (2013), 3007–3018.
36. [36] Zhang, Y., Yan, W., Collins, M.A., Bednar, F., Rakshit, S., Zetter, B.R., Stanger, B.Z., Chung, I., Rhim, A.D., di Magliano, M.P., Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res. 73:20 (2013), 6359–6374.
37. [37] Karnevi, E., Andersson, R., Rosendahl, A.H., Tumour-educated macrophages display a mixed polarisation and enhance pancreatic cancer cell invasion. Immunol. Cell Biol. 92:6 (2014), 543–552.
38. [38] Bassaganas, S., Allende, H., Cobler, L., Ortiz, M.R., Llop, E., de Bolos, C., Peracaula, R., Inflammatory cytokines regulate the expression of glycosyltransferases involved in the biosynthesis of tumor-associated sialylated glycans in pancreatic cancer cell lines. Cytokine 75:1 (2015), 197–206.
39. [39] Miura, T., Mitsunaga, S., Ikeda, M., Shimizu, S., Ohno, I., Takahashi, H., Furuse, J., Inagaki, M., Higashi, S., Kato, H., Terao, K., Ochiai, A., Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels. Pancreas 44:5 (2015), 756–763.
40. [40] Fujiwara, Y., Kobayashi, T., Chayahara, N., Imamura, Y., Toyoda, M., Kiyota, N., Mukohara, T., Nishiumi, S., Azuma, T., Yoshida, M., Minami, H., Metabolomics evaluation of serum markers for cachexia and their intra-day variation in patients with advanced pancreatic cancer. PLoS One, 9(11), 2014, e113259.
41. [41] Gilabert, M., Calvo, E., Airoldi, A., Hamidi, T., Moutardier, V., Turrini, O., Iovanna, J., Pancreatic cancer-induced cachexia is Jak2-dependent in mice. J. Cell. Physiol. 229:10 (2014), 1437–1443.
42. [42] Martignoni, M.E., Dimitriu, C., Bachmann, J., Krakowski-Rosen, H., Ketterer, K., Kinscherf, R., Friess, H., Liver macrophages contribute to pancreatic cancer-related cachexia. Oncol. Rep. 21:2 (2009), 363–369.
43. [43] Zhang, D., Zhou, Y., Wu, L., Wang, S., Zheng, H., Yu, B., Li, J., Association of IL-6 gene polymorphisms with cachexia susceptibility and survival time of patients with pancreatic cancer. Ann. Clin. Lab. Sci. 38:2 (2008), 113–119.
44. [44] Huang, C., Yang, G., Jiang, T., Huang, K., Cao, J., Qiu, Z., Effects of IL-6 and AG490 on regulation of Stat3 signaling pathway and invasion of human pancreatic cancer cells in vitro. J. Exp. Clin. Cancer Res.: CR, 29, 2010, 51.
45. [45] Maes, M., Scharpe, S., Meltzer, H.Y., Bosmans, E., Suy, E., Calabrese, J., Cosyns, P., Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res. 49:1 (1993), 11–27.
46. [46] Musselman, D.L., Miller, A.H., Porter, M.R., Manatunga, A., Gao, F., Penna, S., Pearce, B.D., Landry, J., Glover, S., McDaniel, J.S., Nemeroff, C.B., Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am. J. Psychiatry 158:8 (2001), 1252–1257.
47. [47] Tsukinaga, S., Kajihara, M., Takakura, K., Ito, Z., Kanai, T., Saito, K., Takami, S., Kobayashi, H., Matsumoto, Y., Odahara, S., Uchiyama, K., Arakawa, H., Okamoto, M., Sugiyama, H., Sumiyama, K., Ohkusa, T., Koido, S., Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy. World J. Gastroenterol. 21:39 (2015), 11168–11178.
48. [48] Dima, S.O., Tanase, C., Albulescu, R., Herlea, V., Chivu-Economescu, M., Purnichescu-Purtan, R., Dumitrascu, T., Duda, D.G., Popescu, I., An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma. Pancreas 41:7 (2012), 1001–1007.
49. [49] Moses, A.G., Maingay, J., Sangster, K., Fearon, K.C., Ross, J.A., Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival. Oncol. Rep. 21:4 (2009), 1091–1095.
50. [50] Mroczko, B., Groblewska, M., Gryko, M., Kedra, B., Szmitkowski, M., Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis. J. Clin. Lab. Anal. 24:4 (2010), 256–261.
51. [51] Ebrahimi, B., Tucker, S.L., Li, D., Abbruzzese, J.L., Kurzrock, R., Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 101:12 (2004), 2727–2736.
52. [52] Bellone, G., Smirne, C., Mauri, F.A., Tonel, E., Carbone, A., Buffolino, A., Dughera, L., Robecchi, A., Pirisi, M., Emanuelli, G., Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol. Immunother.: CII 55:6 (2006), 684–698.
53. [53] Denley, S.M., Jamieson, N.B., McCall, P., Oien, K.A., Morton, J.P., Carter, C.R., Edwards, J., McKay, C.J., Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma. J. Gastrointest. Surg. 17:5 (2013), 887–898.
54. [54] Tsukinaga, S., Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy. World J. Gastroenterol., 21(39), 2015, 11168.
55. [55] Mitsunaga, S., Ikeda, M., Shimizu, S., Ohno, I., Furuse, J., Inagaki, M., Higashi, S., Kato, H., Terao, K., Ochiai, A., Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer 108:10 (2013), 2063–2069.
56. [56] Goumas, F.A., Holmer, R., Egberts, J.H., Gontarewicz, A., Heneweer, C., Geisen, U., Hauser, C., Mende, M.M., Legler, K., Rocken, C., Becker, T., Waetzig, G.H., Rose-John, S., Kalthoff, H., Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer. Int. J. Cancer 137:5 (2015), 1035–1046.
57. [57] Lui, G.Y., Kovacevic, Z., Menezes, S.V., Kalinowski, D.S., Merlot, A.M., Sahni, S., Richardson, D.R., Novel thiosemicarbazones regulate the signal transducer and activator of transcription 3 (STAT3) pathway: inhibition of constitutive and interleukin 6-induced activation by iron depletion. Mol. Pharmacol. 87:3 (2015), 543–560.
58. [58] Peng, M., Huang, B., Zhang, Q., Fu, S., Wang, D., Cheng, X., Wu, X., Xue, Z., Zhang, L., Zhang, D., Da, Y., Dai, Y., Yang, Q., Yao, Z., Qiao, L., Zhang, R., Embelin inhibits pancreatic cancer progression by directly inducing cancer cell apoptosis and indirectly restricting IL-6 associated inflammatory and immune suppressive cells. Cancer Lett. 354:2 (2014), 407–416.
59. [59] Lang, S.A., Moser, C., Gaumann, A., Klein, D., Glockzin, G., Popp, F.C., Dahlke, M.H., Piso, P., Schlitt, H.J., Geissler, E.K., Stoeltzing, O., Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clin. Cancer Res. 13:21 (2007), 6459–6468.
60. [60] Catanzaro, R., Celep, G., Zerbinati, N., Papacharalambous, M., Nagpal, R., Marotta, F., Rastmanesh, R., Milazzo, M., Lorenzetti, A., Bertuccelli, G., Sollano, J., In vitro protective effect of celergen, a bioactive marine compound, on interleukin-6-related invasiveness of pancreatic cancer. Acta Bio-med.: Atenei Parm. 85:1 (2014), 44–51.
61. [61] Bao, B., Ali, S., Ahmad, A., Azmi, A.S., Li, Y., Banerjee, S., Kong, D., Sethi, S., Aboukameel, A., Padhye, S.B., Sarkar, F.H., Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PLoS One, 7(12), 2012, e50165.
62. [62] Huang, X., Dai, S., Dai, J., Xiao, Y., Bai, Y., Chen, B., Zhou, M., Luteolin decreases invasiveness, deactivates STAT3 signaling, and reverses interleukin-6 induced epithelial–mesenchymal transition and matrix metalloproteinase secretion of pancreatic cancer cells. OTT, 2015, 2989.
63. [63] Guan, J., Zhang, H., Wen, Z., Gu, Y., Cheng, Y., Sun, Y., Zhang, T., Jia, C., Lu, Z., Chen, J., Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells. Cancer Lett. 345:1 (2014), 132–139.
64. [64] Zhang, J., Wang, P., Ouyang, H., Yin, J., Liu, A., Ma, C., Liu, L., Targeting cancer-related inflammation: chinese herbal medicine inhibits epithelial-to-mesenchymal transition in pancreatic cancer. PLoS One, 8(7), 2013, e70334.
65. [65] Ouyang, H.Q., Liu, L.M., Chen, Z., Luo, J.M., Yu, E.X., Effects of Qingyi Huaji decoction on serum levels of interleukin-6, interleukin-8 and tumor necrosis factor-alpha in nude mice bearing pancreatic tumors. Zhong Xi Yi Jie He Xue Bao = J. Chin. Integr. Med. 8:7 (2010), 655–661.